Analyst Reco. Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.3 ^USD	-4.55%		+0.64%	-29.92%

May. 07	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT
May. 06	Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	May. 07	MT
Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating	Jan. 29	MT
Stifel Adjusts Price Target on Travere Therapeutics to $10 From $8, Maintains Hold Rating	Dec. 18	MT
Citigroup Upgrades Travere Therapeutics to Buy From Neutral, Raises Price Target to $10 From $7	Dec. 05	MT
JPMorgan Adjusts Travere Therapeutics Price Target to $19 From $23, Maintains Overweight Rating	Nov. 24	MT
Citigroup Initiates Travere Therapeutics With Neutral Rating, $7 Price Target	Nov. 20	MT
Canaccord Genuity Cuts Travere Therapeutics Price Target to $15 From $35, Maintains Buy Rating	23-10-03	MT
Guggenheim Cuts Travere Therapeutics' Price Target to $18 From $25, Keeps Buy Rating	23-09-22	MT
Evercore ISI Adjusts Price Target on Travere Therapeutics to $14 From $30, Maintains Outperform Rating	23-09-22	MT
HC Wainwright Adjusts Travere Therapeutics' Price Target to $18 From $32, Keeps Buy Rating	23-09-22	MT
Wells Fargo Downgrades Travere Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $8 From $24	23-09-22	MT
Wedbush Lowers Travere Therapeutics' PT to $12 From $23, Revises Estimates to Assume 'Worst-Case Scenario' With Filspari Remaining on US Market Through 2026; Keeps Outperform Rating	23-09-22	MT
William Blair Downgrades Travere Therapeutics to Market Perform From Outperform	23-09-21	MT
Evercore ISI Reinstates Travere Therapeutics at Outperform, $30 Price Target	23-09-06	MT
Piper Sandler Adjusts Travere Therapeutics' Price Target to $19 From $22, Keeps Neutral Rating	23-08-18	MT
Travere Therapeutics' Shares Rise After JPMorgan Initiates Coverage	23-07-21	MT
JPMorgan Initiates Travere Therapeutics With Overweight Rating, $26 Price Target	23-07-21	MT
Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $35 From $37, Maintains Buy Rating	23-07-18	MT
Piper Sandler Assumes Travere Therapeutics at Neutral With $22 Price Target	23-06-07	MT
HC Wainwright Adjusts Price Target on Travere Therapeutics to $35 From $22, Reiterates Buy Rating	23-06-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Analyst Reco.

Filters